All In Biotech

Drug Trial Radar · NCT04073680

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors With PIK3CA or KRAS Mutations

Last checked: Nov 19, 2026Latest source record: May 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Planned (sponsor's estimate)

Start

Sep 1, 2020

Primary completion

Jul 15, 2021

Study completion Dec 30, 2021

Sponsor

Lead sponsor
Petra PharmaIndustry
Sponsor type
Industry
First posted
Aug 29, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to test the hypothesis that combining serabelisib, a PI3K alpha isoform inhibitor, with an SGLT2 inhibitor, canagliflozin will improve efficacy in the treatment of patients with advanced solid tumors.

Conditions

  • Breast Cancer
  • Endometrial Cancer
  • Lung Cancer
  • Colo-rectal Cancer
  • Head and Neck Cancer

Interventions

  • SerabelisibDrug

    Subjects will be dosed with Serabelisib on 3 consecutive days a week in a 28 day cycle until tumor progression. in combination with Canagliflozin 300mg, both are oral medications

  • Canagliflozin 300mgDrug

    All subjects will be dosed with 300 mg canagliflozin in combination with serabelisib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Adverse EventsTime frame: 30 days after last dose
  2. Rate of Laboratory AbnormalitiesTime frame: 30 days after last dose
  3. Dose confirmationTime frame: 6 months
  4. Tumor Assessments by RESISTTime frame: 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.